Concepedia

Robbyna Svaerd

RS

1

Publications

38

Citations

1

H-Index

2013

Active since

Affiliations

Boehringer Ingelheim (Sweden)(Current)

Robbyna Svaerd is an author at Boehringer Ingelheim (Sweden).

Publications per year

2013–2013

1

Publications

1

Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control

Martin Ridderstråle, Robbyna Svaerd, Cordula Zeller et al. · Cardiovascular Diabetology · 2013 · 38 citations · Full text

Rows per page

1–1 of 1